错配修复(MMR)状态对高危中危子宫内膜癌复发的影响
该回顾性队列研究纳入2016至2018年南加州两家医院系统的244例I期高危中危子宫内膜样癌患者,其中86例(35%)为dMMR。dMMR组淋巴血管间隙浸润相对风险较高(RR 1.63,95%CI 1.26-2.10,P=0.0002),深肌层浸润风险较低(RR 0.81,95%CI 0.66-0.99,P=0.047),但复发率及复发时间无差异。
要点
- I期高危中危子宫内膜样癌中dMMR占35%(86/244)。
- dMMR组淋巴血管间隙浸润相对风险高于pMMR组(RR 1.63)。
- dMMR组深肌层浸润相对风险低于pMMR组(RR 0.81)。
核心结论
- 在I期高危中危子宫内膜样癌中,dMMR与pMMR人群的复发率及复发时间无显著差异。
研究设计与样本
- 回顾性病历审查,纳入2016至2018年南加州两家医院系统的I期高危中危子宫内膜样癌患者244例。
主要发现
- 244例中86例(35%)为dMMR。
- dMMR组淋巴血管间隙浸润相对风险高于pMMR组(RR 1.63,95%CI 1.26-2.10,P=0.0002)。
- dMMR组深肌层浸润相对风险低于pMMR组(RR 0.81,95%CI 0.66-0.99,P=0.047)。
- 基于MMR状态的复发率及复发时间无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 25 % of endometrial cancers harbor deficiencies in mismatch repair (dMMR). The clinical impact of this molecular aberration remains undefined in patients with high intermediate risk (HIR) endometrial cancer. METHODS: We conducted a retrospective chart review of women diagnosed with Stage I high-intermediate risk endometrioid endometrial cancer in two hospital systems in Southern California between 2016 and 2018. We collected demographic information, mismatch repair status, pathology reports, and time to recurrence. RESULTS: 244 patients met inclusion criteria, of which 86 (35 %) were found to be dMMR. The dMMR patient population had higher relative risks of lymphovascular space invasion (relative risk 1.63, 95 % confidence interval 1.26-2.10, p-value 0.0002) but were less likely to have deep myometrial invasion (relative risk 0.81, 95 % confidence interval 0.66-0.99, p-value 0.047) when compared to the pMMR EC cohort. No differences were found in the rate of recurrence or time to recurrence based on MMR status. CONCLUSIONS: In this large, multi-institution, cohort study there were no significant differences identified between Stage I HIR dMMR and pMMR endometrioid endometrial cancer populations with regards to recurrence rates or alternate cancer-related outcomes.
引用
- Keverline KJ, Hill B, Hom-Tedla M, et al. Impact of mismatch repair (MMR) status on recurrence in high intermediate risk endometrial cancer. Gynecol Oncol. 2025. PMID: 40334309. doi:10.1016/j.ygyno.2025.04.588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。